Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Monitoring Inflammasome Activation with a Bioluminescent Caspase-1 Assay

Part # PS270


Martha O'Brien1, Danielle Moehring1, Justin Callaway2, Jenny Ting2, Mike Scurria3, Tim Ugo3, Laurent Bernad3, James Cali1 and Dan Lazar1
1Promega Corporation, 2800 Woods Hollow Rd, Madison, WI, 53711; 2Dept. of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599; 3Promega Biosciences LLC, 277 Granada Dr, San Luis Obispo, CA 93401

To simplify and provide a more direct means of detecting cell-based caspase-1 activity, we developed a sensitive, homogeneous, plate-based assay that eliminates the need for significant sample processing. The assay employs a single-step format combining a caspase-1 substrate, Z-WEHD-aminoluciferin, with a thermostable luciferase in an optimized, lytic reagent. Assay specificity for caspase-1 is confirmed by the subsequent use of a caspase-1 inhibitor, Ac-YVAD-CHO. The assay can be used to measure caspase-1 activity directly in cell cultures or to monitor released caspase-1 activity in culture medium from treated cells. Using this assay system, caspase-1 activation has been demonstrated in numerous cell culture models of inflammasome activation.

Printed in USA.